Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf089 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Felicia C Chow und 10 weiteren Autor:innen. Beteiligte Einrichtung: Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Linezolid, Tuberculosis, Meningeal, HIV Infections, Antitubercular Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FIC NIH HHS.
Abstract (Originalsprache)
Background
Tuberculous meningitis (TBM)–related deaths occur early, often within weeks after treatment initiation. Enhanced treatment early in the disease course with agents that effectively penetrate the central nervous system may improve outcomes in TBM.
Methods
We conducted a phase 2, open-label, randomized trial in Masaka, Uganda, to assess the safety and tolerability of linezolid 1200 mg once daily versus no linezolid with high-dose (35 mg/kg/d) or standard-dose (10 mg/kg/d) rifampin for 4 weeks in participants with definite or suspected TBM. The primary endpoint was any grade ≥3 adverse event during the interventional period. Secondary endpoints included overall survival and functional independence adjusted for TBM disease grade.
Results
We randomized 40 participants (98% with human immunodeficiency virus [HIV]). One-fourth had microbiologically confirmed TBM. Nearly 75% had moderate to severe disease (Medical Research Council grades II and III). No significant difference in grade ≥3 adverse event–free survival was observed across the 4 treatment arms (P = .18) or by linezolid (P = .97) or rifampin (P = .46) treatment group. More favorable overall survival at 12 and 24 weeks (odds ratio, 0.28 [P = .10] and 0.43 [P = .24], respectively) and functional outcome at 12 and 24 weeks (OR for lower modified Rankin Scale score [ie, less disability], 2.22 [P = .18] and 2.00 [P = .24]) were observed in the linezolid group.
Conclusions
The addition of a short course of linezolid to treat predominantly moderate to severe TBM in adults with HIV did not introduce excess toxicity. Our findings add to growing evidence that linezolid is a safe and acceptable treatment for TBM that merits further investigation in larger multisite trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
- Department of Medicine (Infectious Diseases), University of California, San Francisco, San Francisco, California, USA.
- UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA.
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
- Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
ORCID-Profile: Felicia C Chow, Elana Farrell, Margaret Wilson, Payam Nahid, Fiona Cresswell, Freddie M Kibengo
Förderung
- FIC NIH HHS
Zitieren
APA
Chow, F. C., Kafeero, P., Nakimbugwe, M., Ssemaganda, A., Tayebwa, C., Farrell, E., Wilson, M., Nahid, P., Savic, R., Cresswell, F., & Kibengo, F. M. (2025). Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf089
Vancouver
Chow FC, Kafeero P, Nakimbugwe M, Ssemaganda A, Tayebwa C, Farrell E, et al. Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf089
BibTeX
@article{Chow2025,
author = {Chow, Felicia C and Kafeero, Paddy and Nakimbugwe, Maria and Ssemaganda, Anthony and Tayebwa, Colman and Farrell, Elana and Wilson, Margaret and Nahid, Payam and Savic, Rada and Cresswell, Fiona and Kibengo, Freddie M},
title = {Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf089}
}
EUVIMED